Table 3

Cox regression analysis to determine HRs for NODAT incidence by CEC

HR (95% CI)P value
Model 10.54 (0.38–0.76)0.01
Model 20.53 (0.38–0.76)<0.001
Model 30.65 (0.45–0.93)0.025
Model 40.54 (0.38–0.77)0.01
Model 50.53 (0.37–0.75)<0.001
Model 60.56 (0.39–0.81)0.02
Model 70.52 (0.31–0.88)0.015
Model 80.53 (0.37–0.76)0.004
Model 90.54 (0.38–0.76)<0.001
  • Model 1: crude analysis; model 2: adjustment for age and sex; model 3: model 2 plus adjustment for BMI, waist circumference, and hs-CRP; model 4: model 2 plus adjustment for time since renal transplantation; model 5: model 2 plus adjustment for eGFR and urinary albumin-to-creatinine ratio; model 6: model 2 plus adjustment for serum concentration of insulin and HOMA-IR; model 7: model 2 plus adjustment for total cholesterol, HDL-C, apoA-I, apoB, and triglycerides; model 8: model 2 plus adjustment for use of proliferation inhibitors, calcineurin inhibitors, tacrolimus, cyclosporine, antihypertensives, and daily prednisolone dose; and model 9: model 2 plus adjustment for use of statins.